Preuß Sophie L, Bieber Katja, Vorobyev Artem, Recke Andreas, Moderegger Eva Lotta, Zirpel Henner, Gaffal Evelyn, Thaçi Diamant, Kridin Khalaf, Ludwig Ralf J
Department of Dermatology, University Medical Centre of the State of Schleswig-Holstein (UKSH), Lübeck, Germany.
Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1576-1587. doi: 10.1111/jdv.20670. Epub 2025 Apr 2.
Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.
To retrospectively assess the risk of APOs in dupilumab-treated pregnant women in a large real-world database.
Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy-induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan-Meier method, outcome differences the log-rank test and hazard ratios (HR) the Cox regression model.
During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03-0.45, p = 0.0002) and 'any APO' (HR: 0.53, CI: 0.33-0.84, p = 0.0067) in the dupilumab-treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab-treated and untreated women up to 6 months before pregnancy or during the postpartum period.
This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.
2型慢性炎症性疾病(T2IDs)在育龄女性中高度流行。度普利尤单抗,一种单克隆抗体,越来越多地用于治疗T2IDs。虽然度普利尤单抗在孕期未获批准,但较小规模的研究表明妊娠并发症(不良妊娠结局(APOs))风险并未增加。需要更多数据来更好地评估该药物在孕期的安全性。
在一个大型真实世界数据库中,回顾性评估接受度普利尤单抗治疗的孕妇发生APOs的风险。
从美国TriNetX协作网络中检索孕期患有T2ID且接受过度普利尤单抗治疗的孕妇。孕期患有T2ID但未接受过度普利尤单抗治疗的孕妇作为对照。对人口统计学、诊断、用药情况及假定的APO风险因素进行倾向评分匹配(PSM)。分析的结局包括各种孕产妇妊娠并发症,如早产、妊娠期高血压、妊娠期糖尿病、产褥期感染和自然流产。采用Kaplan-Meier方法进行生存分析,用对数秩检验评估结局差异,用Cox回归模型评估风险比(HR)。
孕期有293名女性使用过度普利尤单抗。PSM后,未发现APOs风险增加。值得注意的是,发现度普利尤单抗治疗组早产风险降低(HR:0.11,置信区间(CI):0.03 - 0.45,p = 0.0002),“任何APO”风险降低(HR:0.5